Shattuck Labs, Inc. (NASDAQ:STTK) Short Interest Update

Shattuck Labs, Inc. (NASDAQ:STTK) was the recipient of a significant decline in short interest in the month of February. As of February 13th, there was short interest totaling 1,921,827 shares, a decline of 14.7% from the January 29th total of 2,251,778 shares. Based on an average daily volume of 334,601 shares, the days-to-cover ratio is presently 5.7 days. Approximately 3.5% of the shares of the company are short sold. Approximately 3.5% of the shares of the company are short sold. Based on an average daily volume of 334,601 shares, the days-to-cover ratio is presently 5.7 days.

Shattuck Labs Price Performance

NASDAQ:STTK opened at $4.73 on Thursday. The company has a 50 day moving average price of $4.08 and a 200-day moving average price of $2.78. Shattuck Labs has a 1-year low of $0.69 and a 1-year high of $4.89. The firm has a market cap of $299.31 million, a price-to-earnings ratio of -4.64 and a beta of 1.55.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Turtle Creek Wealth Advisors LLC purchased a new stake in shares of Shattuck Labs during the 3rd quarter worth about $29,000. Virtu Financial LLC purchased a new position in Shattuck Labs during the third quarter worth approximately $38,000. Squarepoint Ops LLC acquired a new stake in Shattuck Labs in the third quarter valued at approximately $46,000. Mallini Complete Financial Planning LLC acquired a new stake in Shattuck Labs in the fourth quarter valued at approximately $83,000. Finally, Dimensional Fund Advisors LP purchased a new stake in shares of Shattuck Labs in the fourth quarter valued at approximately $85,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on STTK shares. Piper Sandler began coverage on shares of Shattuck Labs in a research note on Wednesday, January 28th. They set an “overweight” rating and a $15.00 price objective for the company. Citigroup raised their target price on shares of Shattuck Labs from $2.00 to $4.00 and gave the stock a “neutral” rating in a report on Tuesday, January 6th. HC Wainwright upgraded shares of Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 target price for the company in a research report on Monday, December 1st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Shattuck Labs in a report on Thursday, January 22nd. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Shattuck Labs presently has an average rating of “Hold” and a consensus target price of $6.20.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.